bufomix easyhaler 320 mikrog / 9 mikrog / inhalaatio inhalaatiojauhe
orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 320 mikrog / 9 mikrog / inhalaatio - formoteroli ja budesonidi
innovair nexthaler 100 mikrog / 6 mikrog / inhalaatio inhalaatiojauhe
chiesi farmaceutici s.p.a - beclometasone dipropionate, formoterol fumarate dihydrate - inhalaatiojauhe - 100 mikrog / 6 mikrog / inhalaatio - formoteroli ja beklometasoni
innovair 200 / 6 mikrog / annos inhalaatiosumute, liuos
chiesi farmaceutici spa - formoterol fumarate dihydrate, beclometasone dipropionate anhydrate - inhalaatiosumute, liuos - 200 / 6 mikrog / annos - formoteroli ja beklometasoni
innovair nexthaler 200 mikrog / 6 mikrog / inhalaatio inhalaatiojauhe
chiesi farmaceutici spa - formoterol fumarate dihydrate, beclometasone dipropionate anhydrate - inhalaatiojauhe - 200 mikrog / 6 mikrog / inhalaatio - formoteroli ja beklometasoni
bufomix easyhaler 80 mikrog / 4,5 mikrog / inhalaatio inhalaatiojauhe
orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 80 mikrog / 4,5 mikrog / inhalaatio - formoteroli ja budesonidi
oxis turbuhaler 6 mikrog/annos inhalaatiojauhe
astrazeneca oy - formoterol fumarate dihydrate - inhalaatiojauhe - 6 mikrog/annos - formoteroli
oxis turbuhaler 12 mikrog/annos inhalaatiojauhe
astrazeneca oy - formoterol fumarate dihydrate - inhalaatiojauhe - 12 mikrog/annos - formoteroli
aforbe 100 / 6 mikrog / annos inhalaatiosumute, liuos
viatris limited - formoterol fumarate dihydrate, beclometasone dipropionate - inhalaatiosumute, liuos - 100 / 6 mikrog / annos - formoteroli ja beklometasoni
fomeda easyhaler 12 mikrog/annos inhalaatiojauhe
orion corporation - formoterol fumarate dihydrate - inhalaatiojauhe - 12 mikrog/annos - formoteroli
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).